Spinal cord injury therapeutics market to grow 6.3% annually to 2017 says report

The report 'Acute Spinal Cord Injury (ASCI) Therapeutics: Pipeline Assessment and Market Forecasts to 2019' estimates the acute spinal cord injury (ASCI) therapeutics market to grow 6.3% annually to hit $68.76m in 2017. This growth is mainly attributed to the increasing incidence of SCIs and a larger treatment seeking population.

The 65 page report reveals that the current competition in the ASCI therapeutics market is weak. The arket lacks a therapy specifically approved by the FDA (Food and Drug Administration) or the EMEA European Medicines Agency) for the treatment of SCIs. Medrol (methylprednisolone), which helps to educe swelling in the spinal cord, is widely prescribed as an off-label drug. However, it is unable to ompletely serve the market’s unmet needs. The absence of effective treatment options clearly signifies hat the current competition in the ASCI market is weak.

View the report: 'Acute Spinal Cord Injury (ASCI) Therapeutics: Pipeline Assessment and Market Forecasts to 2019'

press@reportbuyer.com

44 (0) 20 7060 7474

Reportbuyer.com is the online store for global business information. The website now lists more than 200,000 company overviews, market research reports, industry studies and business books from over 300 specialist publishers. Thousands of professionals from across the world make ReportBuyer.com their first choice in their search for quality business insight.

Tags: